文献速递冠心病血脂与心血管预防

RIVER-PCI 试验:糖尿病与非糖尿病患者不完全血运重建后雷诺嗪的疗效

Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

RIVER-PCI 试验二次分析纳入 2604 例经皮冠状动脉介入治疗后不完全血运重建的慢性心绞痛患者,随机接受雷诺嗪或安慰剂。在 961 例(36.9%)糖尿病患者中,雷诺嗪较安慰剂显著降低 6 个月和 12 个月 HbA1c,并减少 6 个月心绞痛频率,但 12 个月时心绞痛效果消失。

要点

  • 糖尿病亚组中雷诺嗪较安慰剂降低 6 个月 HbA1c 0.42±0.08%、12 个月 0.44±0.08%。
  • 非糖尿病亚组中雷诺嗪较安慰剂降低 6 个月 HbA1c 0.19±0.02%、12 个月 0.20±0.02%。
  • 糖尿病亚组中雷诺嗪较安慰剂显著减少 6 个月心绞痛频率,但 12 个月无显著差异。

核心结论

  • 在糖尿病合并慢性心绞痛且经皮冠状动脉介入治疗后不完全血运重建的患者中,雷诺嗪对血糖控制和 6 个月心绞痛的效果与基线 HbA1c 成比例,但心绞痛效果在 12 个月时消失。

研究设计与样本

  • RIVER-PCI 试验的二次分析,纳入 2604 例慢性心绞痛且经皮冠状动脉介入治疗后不完全血运重建的患者,随机接受雷诺嗪或安慰剂。

主要发现

  • 在糖尿病患者中,雷诺嗪较安慰剂显著降低 6 个月 HbA1c 0.42±0.08%(校正均数差±标准误)和 12 个月 0.44±0.08%。
  • 在非糖尿病患者中,雷诺嗪较安慰剂显著降低 6 个月 HbA1c 0.19±0.02% 和 12 个月 0.20±0.02%。
  • 在糖尿病患者中,雷诺嗪较安慰剂显著减少 6 个月西雅图心绞痛问卷心绞痛频率,但 12 个月无显著差异。
  • 基线 HbA1c ≥7.5% 的患者心绞痛频率降低数值上大于 HbA1c <7.5% 的患者(交互作用 p=0.07)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic angina is more common in patients with diabetes mellitus (DM) with poor glucose control. Ranolazine both treats chronic angina and improves glucose control. OBJECTIVES: This study sought to examine ranolazine's antianginal effect in relation to glucose control. METHODS: The authors performed a secondary analysis of the RIVER-PCI (Ranolazine in Patients with Incomplete Revascularization after Percutaneous Coronary Intervention) trial, a clinical trial in which 2,604 patients with chronic angina and incomplete revascularization following percutaneous coronary intervention were randomized to ranolazine versus placebo. Mixed-effects models were used to compare the effects of ranolazine versus placebo on glycosylated hemoglobin (HbA1c) at 6- and 12-month follow-up. Interaction between baseline HbA1c and ranolazine's effect on Seattle Angina Questionnaire angina frequency at 6 and 12 months was tested. RESULTS: Overall, 961 patients (36.9%) had DM at baseline. Compared with placebo, ranolazine significantly decreased HbA1c by 0.42 ± 0.08% (adjusted mean difference ± SE) and 0.44 ± 0.08% from baseline to 6 and 12 months, respectively, in DM patients, and by 0.19 ± 0.02% and 0.20 ± 0.02% at 6 and 12 months, respectively, in non-DM patients. Compared with placebo, ranolazine significantly reduced Seattle Angina Questionnaire angina frequency at 6 months among DM patients but not at 12 months. The reductions in angina frequency were numerically greater among patients with baseline HbA1c ≥7.5% than those with HbA1c <7.5% (interaction p = 0.07). CONCLUSIONS: In patients with DM and chronic angina with incomplete revascularization after percutaneous coronary intervention, ranolazine's effect on glucose control and angina at 6 months was proportionate to baseline HbA1c, but the effect on angina dissipated by 12 months.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Fanaroff AC, James SK, Weisz G, et al. Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial. J Am Coll Cardiol. 2017. PMID: 28473136. doi:10.1016/j.jacc.2017.02.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。